Massimo Breccia

Pubblicazioni

Titolo Pubblicato in Anno
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience ANNALS OF HEMATOLOGY 2020
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey LEUKEMIA 2020
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance LEUKEMIA & LYMPHOMA 2020
Prognostic Significance of Transcript-Type BCR-ABL1 in Chronic Myeloid Leukemia MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES 2020
Relationship Between High Body Mass Index (BMI) and Treatment Outcomes in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Dasatinib or Imatinib: Retrospective Analysis of the Phase 3 DASISION Trial CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2020
Efficacy and Safety of Asciminib in Heavily Pretreated Patients with Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Sensitivity to Tyrosine Kinase Inhibitors (TKIs) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2020
The advantages and risks of ruxolitinib for the treatment of polycythemia vera EXPERT REVIEW OF HEMATOLOGY 2020
On the road to treatment-free remission in chronic myeloid leukemia: what about `the others'? EXPERT REVIEW OF ANTICANCER THERAPY 2020
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation JOURNAL OF CLINICAL MEDICINE 2020
Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force JOURNAL OF GERIATRIC ONCOLOGY 2020
First Line Treatment with Hydroxyurea in Patients with Policitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria BLOOD 2020
Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome BLOOD 2020
Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION BLOOD 2020
Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib BLOOD 2020
Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial BLOOD 2020
Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study BLOOD 2020
Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival BLOOD 2020
Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study BLOOD 2020
Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the ``Registro Italiano LMC \& Campus CML{''} BLOOD 2020
Hematopoietic Stem Cell Transplantation in Myelofibrosis: The Experience of Three University Transplant Centres in Rome BONE MARROW TRANSPLANTATION 2020

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma